For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Vyndamax and the formulated version represents a significant advancement . These novel therapies stabilize the transthyretin protein, slowing its harmful build-up and alleviating the se